ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Down syndrome in Africa: Challenges, opportunities, and future directions.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Public opinion survey on heritable human genome editing in South Africa: a study protocol.Global health action · 2026Article
- Global and Chinese co-occurrence patterns association with socio-demographic index for congenital heart disease and Down syndrome, 1990-2021.Translational pediatrics · 2026Article
- Down syndrome in Africa: Challenges, opportunities, and future directions.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
introductionAs life expectancy improves for people with Down syndrome (DS) in Africa, the risk of developing DS-associated Alzheimer's disease (DSAD) will rise. There is a pressing need to plan for this emerging challenge, particularly in the context of existing health and social disparities.
methodsThis work emerged from a pan-African collaboration, including discussions at the Brain Ageing and Dementia in Low- and Middle-Income Countries conference held in Nairobi in 2024, where stakeholders identified regional priorities for DS and dementia care.
resultsLimited epidemiological, cognitive, biomarker data, delayed diagnoses, and gaps in specialized services may impact access to care. However, innovative solutions, such as mobile biomarker sampling and culturally adapted cognitive assessments, offer promising strategies. DISCUSSION: Integrating global advances in DSAD research with Africa's strengths in community-based care offers opportunities. By prioritizing research, capacity building, and health system integration, this work advocates for the inclusion of DS in Africa's dementia strategies. HIGHLIGHTS: Projected increases in life expectancy for individuals with Down syndrome (DS) in Africa will lead to a substantial rise in DS-associated Alzheimer's disease (DSAD), necessitating urgent planning and response. There is a critical lack of epidemiological, cognitive, and biomarker data on adults with DS in Africa, hindering accurate diagnosis, care planning, and inclusion in global research. Innovative, scalable solutions-such as mobile biomarker sampling and culturally adapted cognitive assessments-offer an opportunity to integrate scientific advances with Africa's strengths in community-based care. Investment in research and capacity building is essential to address current gaps, reduce disparities, and ensure equitable access to emerging diagnostics and treatments for DSAD across the continent.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.